The monitoring of BCR-ABL mRNA by reverse transcription PCR in patients undergoing allogeneic bone marrow transplantation for acute lymphoblastic leukemia with a positive Philadelphia chromosome
BACKGROUND: Allogeneic bone marrow transplantation (BMT) has been performed as one mode of cure-oriented therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL-Ph' positive). However, the clinical significance of the residual BCR-ABL-positive clones after BMT is still controversial.
PATIENTS AND METHODS: The BCR-ABL gene (p210 and p190) was prospectively studied by nested RT-PCR in 8 ALL-Ph' positive patients undergoing BMT.
RESULTS: All patients received BMT at the time of clinical remission (CR). However, minimal residual disease (MRD) was detected in 7 of them. MRD detected just before BMT seems to be eradicated by BMT protocol. Four patients remained in CR and did not show BCR-ABL transcripts. Other 4 patients, relapsed, demonstrating MRD, which preceded recurrence by a median time of 6 weeks. Three relapsed patients showed p190 transcript and only one, p210 type.
CONCLUSIONS: The RT-PCR assay appears to be a useful test for predicting at high risk of relapse after BMT and may identify patients who might benefit from therapeutic interventions. The finding that the expression of p190 BCR-ABL may carry an especially high risk of relapse suggests a different clinical and biologic behaviour between p190 and p210 BCR-ABL.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1999 |
|---|---|
| Erschienen: |
1999 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:113 |
|---|---|
| Enthalten in: |
Medicina clinica - 113(1999), 20 vom: 11. Dez., Seite 779-82 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Monitorización del ARNm BCR-ABL mediante retrotranscripción PCR en pacientes sometidos a trasplante alogénico de médula ósea por leucemia aguda linfoblástica con cromosoma Filadelfia positivo |
|---|
| Beteiligte Personen: |
Román, J [VerfasserIn] |
|---|
| Themen: |
EC 2.7.10.2 |
|---|
| Anmerkungen: |
Date Completed 02.03.2000 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM106081667 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM106081667 | ||
| 003 | DE-627 | ||
| 005 | 20231222140050.0 | ||
| 007 | tu | ||
| 008 | 231222s1999 xx ||||| 00| ||spa c | ||
| 028 | 5 | 2 | |a pubmed24n0354.xml |
| 035 | |a (DE-627)NLM106081667 | ||
| 035 | |a (NLM)10680143 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Román, J |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The monitoring of BCR-ABL mRNA by reverse transcription PCR in patients undergoing allogeneic bone marrow transplantation for acute lymphoblastic leukemia with a positive Philadelphia chromosome |
| 246 | 3 | 3 | |a Monitorización del ARNm BCR-ABL mediante retrotranscripción PCR en pacientes sometidos a trasplante alogénico de médula ósea por leucemia aguda linfoblástica con cromosoma Filadelfia positivo |
| 264 | 1 | |c 1999 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 02.03.2000 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Allogeneic bone marrow transplantation (BMT) has been performed as one mode of cure-oriented therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL-Ph' positive). However, the clinical significance of the residual BCR-ABL-positive clones after BMT is still controversial | ||
| 520 | |a PATIENTS AND METHODS: The BCR-ABL gene (p210 and p190) was prospectively studied by nested RT-PCR in 8 ALL-Ph' positive patients undergoing BMT | ||
| 520 | |a RESULTS: All patients received BMT at the time of clinical remission (CR). However, minimal residual disease (MRD) was detected in 7 of them. MRD detected just before BMT seems to be eradicated by BMT protocol. Four patients remained in CR and did not show BCR-ABL transcripts. Other 4 patients, relapsed, demonstrating MRD, which preceded recurrence by a median time of 6 weeks. Three relapsed patients showed p190 transcript and only one, p210 type | ||
| 520 | |a CONCLUSIONS: The RT-PCR assay appears to be a useful test for predicting at high risk of relapse after BMT and may identify patients who might benefit from therapeutic interventions. The finding that the expression of p190 BCR-ABL may carry an especially high risk of relapse suggests a different clinical and biologic behaviour between p190 and p210 BCR-ABL | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Fusion Proteins, bcr-abl |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 700 | 1 | |a Castillejo, J A |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez, A |e verfasserin |4 aut | |
| 700 | 1 | |a Maldonado, J |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina clinica |d 1948 |g 113(1999), 20 vom: 11. Dez., Seite 779-82 |w (DE-627)NLM000359017 |x 1578-8989 |7 nnns |
| 773 | 1 | 8 | |g volume:113 |g year:1999 |g number:20 |g day:11 |g month:12 |g pages:779-82 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 113 |j 1999 |e 20 |b 11 |c 12 |h 779-82 | ||